BloodPressureHeartMeds.Org

Rutgers University receives NIH grant to increase reliability of prostate cancer imaging

August 30, 2017

"If we can do these biopsies in a more targeted fashion, we will be more confident that there's no cancer if the biopsy is negative," he said. "From a patient's perspective, that would be far more comforting news."

The grant's principal investigator, Ernest Feleppa, research director of the Lizzi Center for Biomedical Engineering at New York City's Riverside Research Institute, is a pioneer in developing advanced ultrasound technology for imaging prostate cancer. His methods, which analyze ultrasound echo signals in unique ways, show promise for improved guidance of biopsies and targeting of therapies.

Similarly, advanced MR technology performed at Beth Israel Deaconess Medical Center and elsewhere has been able to identify abnormal tissue masses and pinpoint their location within the prostate gland. The reliability of these advanced MR methods is similar to that of Feleppa's advanced ultrasound methods.

Ultrasound signal properties depend on microscopic architecture of tissue while MR signals depend on tissue constituents and other dynamic properties of tissue. The researchers will use computerized tools to align and scale data from both imaging methods, a challenge because of the different resolutions of the two methods and the fact that the MRI is still and the real-time ultrasound image is changing.

Source: Rutgers University